Silenor Shortage: What Providers and Prescribers Need to Know in 2026

Your patients taking Silenor (doxepin 3 mg or 6 mg) for sleep maintenance insomnia may be telling you they can't find it at their pharmacy. This article gives prescribers a clear picture of what's happening with Silenor availability in 2026, how to navigate the brand-versus-generic landscape, and how to counsel patients who are having difficulty filling their prescriptions.

Current Shortage Status (2026)

There is no active FDA or ASHP shortage for doxepin insomnia tablets as of 2026. Manufacturing and distribution are ongoing. However, prescribers should understand that patient difficulty finding Silenor is real and is driven by market and formulary factors rather than supply chain issues.

The Brand Silenor vs. Generic Doxepin Landscape

Generic low-dose doxepin tablets (3 mg and 6 mg) became available in 2020 following patent expiration. As of 2023, generic fills far outpace brand: approximately 292,925 thirty-day supplies of generic low-dose doxepin were dispensed, compared to just 3,019 for brand Silenor (source: JAMA, February 2025). Despite this numerical dominance, generic tablets account for 74% of spending on low-dose doxepin — highlighting significant price disparities.

The mean retail price for a 30-day supply was $526 for brand Silenor and $252 for generic low-dose tablets in 2023. For comparison, generic doxepin 10 mg capsules and liquid doxepin (both used off-label for insomnia) cost $11 and $7 per 30-day supply respectively — representing dramatically lower patient out-of-pocket burden.

Why Patients Can't Find It: A Prescriber's Perspective

When patients report that their pharmacy doesn't have Silenor, the cause is typically one of the following:

Brand-only prescription: If the prescription specifies "Silenor" with "Dispense as Written," pharmacies that only stock the generic cannot substitute. Writing for generic doxepin resolves this immediately.

Pharmacy stocking decisions: Many retail pharmacies have stopped stocking brand Silenor due to low turnover. The pharmacy may have the generic but not the brand.

Prior authorization delays: Many payers require prior authorization for brand Silenor, and step therapy (requiring trial of generic doxepin first) is common. The PA process can delay therapy initiation.

Formulary placement: Brand Silenor is placed on Tier 3 or higher on many formularies, resulting in higher copays that deter patients.

Clinical Considerations for Prescribers

Silenor's clinical profile makes it a useful option for specific patient populations:

Patients with sleep maintenance insomnia specifically (not sleep onset) where histamine blockade provides targeted benefit

Patients who cannot take controlled substances (history of substance use disorder) — Silenor is not DEA-scheduled

Older adults where Z-drugs or benzodiazepines are contraindicated — note Beers Criteria flags doxepin above 6 mg, but at 3–6 mg the risk/benefit is often acceptable

Patients who prefer non-controlled prescription options for convenience (telehealth prescribing, no triplicate requirements)

Prescribing Recommendations to Minimize Dispensing Issues

Write for generic doxepin 3 mg or 6 mg tablets rather than brand Silenor to maximize patient access. Generic substitution is therapeutically equivalent.

Counsel patients to not take within 3 hours of a meal to optimize onset and avoid next-day sedation.

Start elderly patients (≥65 years) at 3 mg/night, with option to increase to 6 mg if tolerated and needed.

Check for cimetidine use — cimetidine significantly increases doxepin exposure and may necessitate dose adjustment.

Verify no MAOI use within the past 2 weeks — absolute contraindication.

Therapeutic Alternatives to Consider

If patients cannot access doxepin at any formulation, consider the following based on clinical profile:

Suvorexant (Belsomra) or lemborexant (Dayvigo): DORAs for sleep onset and maintenance; Schedule IV; appropriate when patients tolerate controlled substances

Ramelteon (Rozerem): Non-controlled melatonin receptor agonist; preferred for sleep-onset insomnia; not effective for isolated sleep maintenance issues

Eszopiclone (Lunesta): GABA-A modulator; approved for onset and maintenance; Schedule IV; generic available

How medfinder Helps Your Patients

Recommending medfinder to patients can reduce the burden on your office by empowering them to locate available pharmacies on their own. medfinder contacts pharmacies near the patient to check which ones have their medication in stock and texts the results.

See also: How to Help Your Patients Find Silenor in Stock: A Provider's Guide for practical communication tools for your practice.